Fulcrum Therapeutics, Inc. (FULC) — Financial statements
Income statement, balance sheet, and cash flow for Fulcrum Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 80↑2752.0% | 3↓55.8% | 6↓66.9% | 19 | |
| Cost of Revenue | 1↓97.8% | 63 | 0.00↓100.0% | 77↑10.2% | 70 | |
| Gross Profit | -1↓108.4% | 17↑492.3% | 3↑104.0% | -70↓39.4% | -51 | |
| Operating Expenses | ||||||
| R&D Expenses | 56↓11.5% | 63↓11.7% | 72↓6.5% | 77↑10.2% | 70 | |
| General & Administrative Expenses | 29↓18.0% | 35↓16.1% | 42↓0.1% | 42↑36.6% | 31 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 1 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 29↓21.4% | 36↓12.5% | 42↓0.1% | 42↑36.6% | 31 | |
| Other Expenses | -1↑97.7% | -61 | 0.00↑100.0% | -76↓9.5% | -70 | |
| Operating Expenses | 83↑116.5% | 39↓66.1% | 113↑169.4% | 42↑38.0% | 31 | |
| Total Costs & Expenses | 85↓16.8% | 102↓10.2% | 113↓4.6% | 119↑18.6% | 100 | |
| Operating Results | ||||||
| Operating Income | -85↓287.1% | -22↑80.2% | -111↑1.7% | -113↓38.9% | -81 | |
| Depreciation & Amortization | 1↓12.7% | 2↓26.7% | 2↓10.0% | 2↓4.0% | 3 | |
| EBITDA | -73↓302.9% | -18↑83.2% | -108↑1.1% | -110↓39.7% | -79 | |
| EBIT | -75↓277.5% | -20↑82.1% | -111↑1.3% | -112↓38.3% | -81 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.21 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.21 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -10↓379.4% | -2 | 0.00↑100.0% | -0.43 | 0.00 | |
| Other Income / Expenses | 10↓18.8% | 12↓8.7% | 13↑395.5% | 3↑1199.5% | 0.21 | |
| Income Before Tax | -75↓670.0% | -10↑90.0% | -97↑11.4% | -110↓35.9% | -81 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -75↓670.0% | -10↑90.0% | -97↑11.4% | -110↓35.9% | -81 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -75↓670.0% | -10↑90.0% | -97↑11.4% | -110↓35.9% | -81 | |
| Bottom-Line Net Income | -75↓670.0% | -10↑90.0% | -97↑11.4% | -110↓35.9% | -81 | |
| EPS (Basic) | -1.18↓637.5% | -0.16↑89.9% | -1.59↑32.3% | -2.35↓5.9% | -2.22 | |
| EPS (Diluted) | -1.18↓637.5% | -0.16↑89.9% | -1.59↑32.3% | -2.35↓5.9% | -2.22 | |
| Weighted Average Shares | 63↑2.2% | 62↑1.1% | 61↑36.3% | 45↑27.2% | 35 | |
| Weighted Average Diluted Shares | 63↑2.2% | 62↑1.1% | 61↑36.3% | 45↑27.2% | 35 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.